Menu
Back to Journals » Adolescent Health, Medicine and Therapeutics » Volume 2
Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
Authors Dobroszycki, Abadi J, Wiznia A, Rosenberg
Published 14 September 2011 Volume 2011:2 Pages 85—93
DOI https://doi.org/10.2147/AHMT.S11177
Review by Single anonymous peer review
Peer reviewer comments 3
Joanna Dobroszycki, Jacobo Abadi, Andrew A Wiznia, Michael G Rosenberg
Department of Pediatrics, Division of Infectious Diseases, Jacobi Medical Center, Bronx, NY, USA
Abstract: The introduction of protease inhibitors (PI) containing antiretroviral regimens in the treatment of HIV infection in infants, children, and adolescents has dramatically decreased morbidity and mortality. Darunavir, the latest PI to be FDA approved for pediatric patients older than 6 years and currently the preferred PI for use in adult patients, was added as an alternative PI for use in children based on a combination of data from both adult and pediatric trials. This review of darunavir in the treatment of HIV-infected children and adolescents looks at the major published clinical trials findings, pharmacokinetic and resistance studies, and preliminary data on use in younger children.
Keywords: darunavir, HIV, protease inhibitor
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.